The combination of contraceptive drugs Drospirenone and ethinyl estradiol has been associated with a number of Drospirenone side effects. Bayer, the manufacturer of oral contraceptives containing the Drospirenone drug is now facing thousands of Drospirenone lawsuits.
FREE CASE EVALUATION
Send your Drospirenone claim to a Lawyer who will review your case at NO COST or obligation. 
Drospirenone
Drospirenone, in combination with ethinyl estradiol, is used as an oral contraceptive in brand names such as Yasmin, Yaz and Safyral, (all made by Bayer) and Ocella, the generic brand of Yasmin (marketed and distributed by Barr Laboratories). These birth control pills, known as “4th generation” contraceptive pills, have also been used to treat the symptoms of menopause, moderate acne and osteoporosis.
Oral contraceptives such as Yasmin and Yaz, Safyral and Ocella contain the synthetic progesterone called drospirenone, which other and traditional oral contraceptives do not contain. The following contraceptives contain drospirenone:
- Yaz
- Yasmin
- Ocella
- Safyral
- Syeda
- Zarah
- Beyaz
- Gianvi
- Loryna
See the FDA website for more information on FDA-approved oral birth control pills with drospirenone.
Drospirenone acts as a female hormone that helps regulate ovulation and menstruation, while estradiol is a female hormone involved in development and maintenance of the female reproductive system.
Drospirenone Side Effects
Drospirenone and Heart Attack. Drospirenone (similar to other medicines typically used as diuretics such as Spironolactone), combined with ethinyl estradiol, has shown an increase in the blood’s potassium levels. This increase can lead to hyperkalemia, which can result in cardiac arrest. Hyperkalemia often has no symptoms, and is often detected after serious heart conditions have already occurred.
Drospirenone and Venous Thromboembolism (VTE). Drospirenone has also been associated with venous thromboembolism (VTE)—blood clots that form within a vein. A number of studies, most recently published in the BMJ (October 2011), suggest that women on these pills (listed above) containing one of the newer types of progestogen hormone (drospirenone, desogestrel or gestodene) have double the risk of VTE than women on pills containing an older progestogen (levonorgestrel). 
Drospirenone and Deep Vein Thrombosis (DVT). Drospirenone has also been linked to deep vein thrombosis (DVT), which is a blood clot that forms in a deep vein, and pulmonary embolism—blood clots in the lungs. New research published in the Canadian Medical Association Journal (November, 2011) involving about 330,000 women in Israel found that women taking birth-control pills containing the drospirenone were as much as 65 per cent more likely to develop venous thromboembolism than women taking older generations of the pill.
Drospirenone and Gallbladder disease. It is also associated with gallbladder disease, particularly in young women.
As early as November 2009 the FDA had reports of 993 cases of pulmonary embolism (PE), 487 cases of DVT and 229 cases of other blood clots for Drospirenone and ethinyl estradiol combined.
The FDA and Drospirenone
The FDA released a safety announcement (September 2011) indicating a 1.5-fold increase in the risk of blood clots for women who use drospirenone-containing birth control pills compared to users of other hormonal contraceptives. In December 2011, an FDA advisory panel voted overwhelmingly to strengthen the warnings on drospirenone-containing birth control, to warn patients about the risk of blood clots associated with the contraceptives. The panel voted to keep the birth control on the market, although that vote was close, at 15 to 11.
The agency announced that a final report of its study that evaluated the risk of blood clots in users of several different hormonal contraceptives will be presented and discussed at the joint meeting of the Reproductive Health Drugs Advisory Committee on December 8, 2011.
In November 2011, Health Canada announced that its review found 1.5 to 3.0 times the risk of blood clots in women who used contraceptives that contain drospirenone. The health agency said that labels have been updated to include the warning and recommended that health care professionals consider the risks and benefits of birth control products that contain drospirenone when determining which contraceptives to prescribe.
Drospirenone Lawsuits
Bayer reported in mid-October 2009 that only 129 Yaz and Yasmin lawsuits had been filed in the US. As of February 2010, about 1,100 lawsuits had been filed in the US against Bayer, which said its product was no riskier than any other oral contraceptive on the market.
According to the Canadian Broadcasting Corp (CBC), by January 2011 more than 4,000 women in the US have taken legal action against Bayer and more than 800 women have joined a class action lawsuit in Canada.
Drospirenone lawsuits against Bayer—both involving side effects and deceptive marketing of Yaz and Yasmin--allege that the drug company:
- Underplayed the risks associated with the products and overstated their approved uses in an effort to mislead users of Yaz and Yasmin into believing that the drugs were safe.
- Failed to properly research the medication.
- Failed to recall the drug after post-marketing reports demonstrated that the risk of potentially life-threatening side effects of Yasmin and Yaz outweighed potential benefits that could be achieved via other available oral contraceptives.
Drospirenone Legal Help
If you or a loved one has suffered damages in this case, please click the link below and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.
Last updated on May-7-12 |
DROSPIRENONE ARTICLES AND INTERVIEWS
651 Yaz/Yasmin Lawsuits Settled for $142 Million
 Berlin, Germany: Bayer AG, the manufacturer of Yaz/Yasmin birth control pills, has announced that it has settled 651 US Yasmin blood clot lawsuits for a total, so far, of $142 million. This makes the average settlement about $218,000 a case [READ MORE]
FDA Changes Labeling on Drospirenone Birth Control and Blood Clots
 Washington, DC: The Food and Drug Administration (FDA) announced today that it is revising the labels for drospirenone-containing birth control pills, warning of the higher associated risk for blot clots [READ MORE]
Did Suspected Advisory Panel Bias Affect Safyral et al Vote?
 Washington, DC: Given that the new-age contraceptive Safyral contains drospirenone (DRSP) and estradiol (EE), it is not surprising to see that the Bayer-manufactured product was tagged with the same concerns—and label updates—as other products in the Bayer family containing that specific formulation.
C [READ MORE]
YOUR DROSPIRENONE STORIES
Publish your Drospirenone experience here for our readers to learn from.
|
